Phase II evaluation of the combination of triazinate, cyclophosphamide, doxorubicin, and cis-diamminedichloroplatinum(II)in patients with advanced adenocarcinoma of the lung

R. T. Eagan, S. Frytak, J. N. Ingle, E. T. Creagan, W. C. Nichols, L. K. Kvols

Research output: Contribution to journalArticlepeer-review

5 Scopus citations

Abstract

In an attempt to improve upon the 43%-48% regression rates noted for various CAP regimens consisting of cyclophosphamide,doxorubicin (Adriamycin), and cis-diamminedichloroplatinum(II) in various doses and schedules, triazinate was added to tht three-drug combination, and the new combination (T-CAP) was evaluated inpatients with advanced adenocarcinoma of the lung.(T-CAP) produced a regression rate of 57% with a 7-week increase in overall median time to progression and a 4-weeks incrase in overall median survival compared to the best of the CAP schedules. More stomatitis and dermatitis were noted with he new combination, but myelosuppression was similar to that of the CAP regimens. These data suggest that further studies wih triazinate should be conducted in patients with adenocarcinoma of the lung.

Original languageEnglish (US)
Pages (from-to)925-928
Number of pages4
JournalCancer Treatment Reports
Volume64
Issue number8-9
StatePublished - Dec 1 1980

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Phase II evaluation of the combination of triazinate, cyclophosphamide, doxorubicin, and cis-diamminedichloroplatinum(II)in patients with advanced adenocarcinoma of the lung'. Together they form a unique fingerprint.

Cite this